Welcome to our dedicated page for Asahi Kaisei Adr news (Ticker: AHKSY), a resource for investors and traders seeking the latest updates and insights on Asahi Kaisei Adr stock.
Asahi Kasei reports developments across a diversified global business that includes healthcare, materials, electronic components, and hydrogen-related technologies. News commonly covers pharmaceutical pipeline expansion, specialty pharmaceutical acquisitions, antiviral and autoimmune-disease programs, and subsidiary activity involving Veloxis Pharmaceuticals, Asahi Kasei Therapeutics, and Asahi Kasei Pharma.
Company updates also include Asahi Kasei Microdevices' magnetic-sensor and photonic technology work, chlor-alkali electrolysis products such as electrolyzer cells, ion-exchange membranes, and electrodes, and Aqualyzer™ alkaline-water electrolyzer deployments for hydrogen production. Recurring themes include research collaborations, license agreements, clinical and regulatory disclosures, material agreements, capital-structure updates, and operating and financial results.
Asahi Kasei (OTC: AHKSY) held a grand opening on August 20 for a new Hipore™ wet-process lithium-ion battery separator coating line at its Celgard® facility in Charlotte, North Carolina. The investment adds North America-based coating and supply capacity, with commercial production planned for the second half of fiscal 2026.
The project is the first step in a regional wet-process separator supply structure, complements Celgard® dry-process output, and is aligned with a capacity rights agreement with Toyota Tsusho and a planned wet-process separator plant in Canada.
Asahi Kasei (OTC: AHKSY) has developed a novel lithium pre-doping technology for high-voltage lithium-ion batteries with silicon-based anodes. By using electrolyte additives, the process decomposes low-cost lithium carbonate at typical cell voltages, enabling it to act as a sacrificial lithium source during the first charge.
According to Asahi Kasei, internal tests on an NMC cell with a 90% graphite / 10% SiO anode showed a 10% increase in energy density. The technology is designed to improve cycle life and cost per Wh, be implemented on existing production lines, and work across various cathode/anode systems. The company plans global PoC evaluations and intends to license the technology as part of its Technology-value Business Creation initiative, targeting at least 10 new license agreements in fiscal 2025–2027 and cumulative profit contribution of ¥10 billion or more by around 2030.
Asahi Kasei (OTC: AHKSY) received regional economic incentives from Kanagawa Prefecture and the City of Kawasaki to support new facilities for alkaline water electrolysis and ion-exchange membrane chlor-alkali electrolysis equipment at its Kawasaki plant in Japan.
The company is constructing new capacity for cell frames and membranes targeting at least 2 GW each by 2028, which, combined with existing chlor-alkali capacity, is expected to lift total annual capacity to over 3 GW. According to Asahi Kasei, the Kawasaki site will be positioned as a key global hub for water electrolysis and chlor-alkali systems, underpinning a flexible supply platform for clean hydrogen and contributing to regional economic development. The project follows Japanese governmental support selected in December 2024 and formal internal approval in October 2025.
Asahi Kasei (OTC: AHKSY) signed its first non-exclusive license agreement in China with HighChem Shanghai to produce and sell Acetolyte™, an acetonitrile-containing electrolyte for lithium-ion batteries. The deal leverages HighChem Shanghai’s customer base to expand Acetolyte™ adoption and supports Asahi Kasei’s licensing-focused Technology-value Business Creation strategy, which targets at least 10 new license agreements in fiscal 2025–2027 and a cumulative profit contribution of ¥10 billion or more by around 2030.
Asahi Kasei (OTCMKTS: AHKSY) has built a new slitting facility for its SUNFORT™ dry film photoresist (DFR) at the Tainan, Taiwan site, completed July 3, with commercial operations starting in July 2026. The approximately ¥2 billion investment adds state-of-the-art equipment and strict cleanroom standards, targeting a 40% capacity increase with potential to double output, supporting growing demand for advanced semiconductor packaging driven by AI.
Asahi Kasei (OTCMKTS:AHKSY) installed its novel forward osmosis–membrane distillation (FO–MD) system at Japanese CDMO Peptistar for trial API manufacturing at GMP-evaluated scale.
The FO–MD system concentrates heat‑sensitive peptide and oligonucleotide APIs without heat or pressure, shortening freeze‑drying time for batches up to 100 L, supporting Asahi Kasei’s Life Science growth strategy.
Asahi Kasei (OTCMKTS: AHKSY) and German manufacturer EAS Batteries began sales of an ultra-high-power cylindrical LFP cell using Acetolyte™, an acetonitrile-containing electrolyte. The UHP601300 LFP 22 cell delivers 2,550 W/kg continuous power (60% above conventional cells) and 3,760 W/kg pulse power, with 2,400-cycle life to 80% capacity at 5C/5C, 100% DoD.
The partners plan sublicensing to global OEMs, are developing a 46xxx format for low-voltage EV batteries with launch targeted for 2026, and pursue an asset-light licensing model within Asahi Kasei’s medium-term management plan.
Asahi Kasei Life Science (OTC:AHKSY) acquired license rights to a novel antibody-drug conjugate (ADC) technology from The Noguchi Institute. The modality allows precise control of drug-to-antibody ratio and attachment sites for single- and dual-payload ADCs.
The technology’s molecular structure conformity is expected to improve predictability of efficacy and safety, enabling stable therapeutic effects and potential treatment of more diseases with better specificity and potentially less toxicity. Both parties will pursue commercialization, possible sub-licensing to biopharma and CDMOs such as Bionova Scientific, and joint research.
Asahi Kasei (AHKSY) announced a new photosensitive polyimide (PSPI) film for advanced panel-level semiconductor packaging. The film combines PIMEL™ liquid PSPI and SUNFORT™ dry film photoresist, targeting improved productivity via easy, uniform lamination on large panels and support for more insulating layers.
The PSPI film is under customer evaluation, with commercial launch expected soon. It is expected to be used in redistribution layers and package substrate insulation, and can be combined with SUNFORT™ TA and CX series for fine circuits and high-aspect-ratio copper pillars in 3D packaging.
Asahi Kasei Microdevices (OTC:AHKSY) introduced its new AK491x series premium audio operational amplifiers, the single-channel AK4911 and dual-channel AK4912. The devices extend AKM’s VELVET SOUND™ concept into the analog output stage and will be showcased at HIGH END Vienna 2026.
The AK491x series targets high-end DAC applications with ultra-low noise of 0.96 nV/√Hz, THD+N of −150 dB at 1 kHz, and ±100 mA output drive, with samples available now and mass production planned for early 2027.